| - |
Atezolizumab |
Tecentriq® |
In combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease. |
NCPE Assessment Process Complete |
1st September 2020 |
 |
| 19030 |
Atezolizumab |
Tecentriq® |
In combination with carboplatin and etoposide is indicated for first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). |
NCPE Assessment Process Complete |
24th September 2020 |
|
| 20060 |
Atezolizumab in combination with bevacizumab |
Tecentriq® |
For the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy. |
NCPE Assessment Process Complete |
8th May 2023 |
|
| 20039 |
Atezolizumab |
Tecentriq® |
Atezolizumab monotherapy is indicated as treatment of locally advanced or metastatic urothelial carcinoma (LaMUC) in adult patients who are considered cisplatin-ineligible and whose tumours have PD-L1 expression ≥5%. |
Rapid Review Complete |
23rd September 2020 |
|
| 21009 |
Atidarsagene autotemcel |
Libmeldy® |
For the treatment of metachromatic leukodystrophy characterized by biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity, in children with late infantile or early juvenile forms without clinical manifestations of the disease, and in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline. |
NCPE Assessment Process Complete |
30th September 2022 |
|
| 23039 |
Atogepant |
Aquipta® |
Prophylaxis of migraine in adults who have at least 4 migraine days per month |
Rapid Review Complete |
21st August 2023 |
|
| 21005 |
Autologous anti-CD19-transduced CD3+ cells |
Tecartus® |
For the treatment of adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor. |
Rapid Review Complete |
17th July 2023 |
|
| 22009 |
Avacopan |
Tavneos® |
In combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis or microscopic polyangiitis. |
NCPE Assessment Process Complete |
20th July 2023 |
|
| - |
Avanafil |
Spedra® |
For the treatment of erectile dysfunction in adult men. |
Rapid Review Complete |
2nd May 2014 |
|
| 20006 |
Avatrombopag |
Doptelet® |
For the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. |
Rapid Review Complete |
2nd April 2020 |
|
| 20058 |
Avatrombopag |
Doptelet® |
For the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). |
Rapid Review Complete |
15th February 2021 |
|
| - |
Avelumab |
Bavencio® |
For the treatment of adults with metastatic Merkel Cell Carcinoma. |
NCPE Assessment Process Complete |
9th October 2018 |
|
| 19046 |
Avelumab |
Bavencio® |
Avelumab in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. |
NCPE Assessment Process Complete |
23rd June 2021 |
|
| 21001 |
Avelumab |
Bavencio® |
As monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma whose disease has not progressed with first line platinum-based induction chemotherapy. |
NCPE Assessment Process Complete |
22nd December 2021 |
|
| - |
Axicabtagene Ciloleucel |
Yescarta® |
For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. |
NCPE Assessment Process Complete |
25th February 2020 |
|
| 22066 |
Axicabtagene ciloleucel |
Yescarta® |
For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. |
Full HTA submission received from Applicant |
6th September 2023 |
|
| - |
Axitinib |
Inlyta® |
For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine |
Rapid Review Complete |
20th November 2012 |
|
| - |
Azelastine hydrochloride and fluticasone propionate (nasal spray) |
Dymista® |
For symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient. |
Rapid Review Complete |
28th February 2013 |
|
| - |
Azilsartan |
Edarbi® |
For the treatment of essential hypertension in adults. |
Rapid Review Complete |
11th January 2012 |
|
| 22070 |
Oral Azacitidine |
Onureg® |
For maintenance treatment in adult patients with acute myeloid leukaemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, haematopoietic stem cell transplantation. |
Rapid Review Complete |
23rd December 2022 |
|
